The aim of our study was to evaluate the role of mutations in the MAPT gene in patients with pure amyotrophic lateral sclerosis (ALS). A cohort of 120 ALS patients, both sporadic and familial, without cognitive impairment was analyzed by next-generation sequencing with a multiple-gene panel comprising 23 genes, including MAPT, known to be associated with ALS and frontotemporal dementia. The presence of the C9orf72 expansion was also investigated. Twelve patients had mutations in the SOD1, TARDBP, MATR3, and FUS genes, while 10 patients carried the C9orf72 expansion. One female patient was found to carry the D348G mutation in MAPT, previously reported in an Italian family with lower motor neuron disease. Our patient presented both upper and lower motor neuron signs, early development of dyspnea, resting and kinetic tremor, and a slow disease course (> 11 years). The present case further broadens the clinical phenotype associated with MAPT mutations and suggests that, although rarely, MAPT mutations can cause ALS and, therefore, should be analyzed in ALS patients, especially in those with early breathing difficulties and long-lasting disease.

1.
Taylor
JP
,
Brown
RH
 Jr
,
Cleveland
DW
.
Decoding ALS: from genes to mechanism
.
Nature
.
2016
Nov
;
539
(
7628
):
197
206
.
[PubMed]
0028-0836
2.
Rosen
DR
,
Siddique
T
,
Patterson
D
,
Figlewicz
DA
,
Sapp
P
,
Hentati
A
, et al.
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
.
Nature
.
1993
Mar
;
362
(
6415
):
59
62
.
[PubMed]
0028-0836
3.
Hardiman
O
,
Al-Chalabi
A
,
Chiò
A
,
Corr
EM
,
Logroscino
G
,
Robberecht
W
, et al.
Amyotrophic lateral sclerosis
.
Nat Rev Dis Primers
.
2017
Oct
;
3
:
17071
.
[PubMed]
2056-676X
4.
Chia
R
,
Chiò
A
,
Traynor
BJ
.
Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications
.
Lancet Neurol
.
2018
Jan
;
17
(
1
):
94
102
.
[PubMed]
1474-4422
5.
Renton
AE
,
Chiò
A
,
Traynor
BJ
.
State of play in amyotrophic lateral sclerosis genetics
.
Nat Neurosci
.
2014
Jan
;
17
(
1
):
17
23
.
[PubMed]
1097-6256
6.
Van Damme
P
,
Robberecht
W
,
Van Den Bosch
L
.
Modelling amyotrophic lateral sclerosis: progress and possibilities
.
Dis Model Mech
.
2017
May
;
10
(
5
):
537
49
.
[PubMed]
1754-8403
7.
Zarranz
JJ
,
Ferrer
I
,
Lezcano
E
,
Forcadas
MI
,
Eizaguirre
B
,
Atarés
B
, et al.
A novel mutation (K317M) in the MAPT gene causes FTDP and motor neuron disease
.
Neurology
.
2005
May
;
64
(
9
):
1578
85
.
[PubMed]
0028-3878
8.
Münch
C
,
Prechter
F
,
Xu
R
,
Linke
P
,
Prudlo
J
,
Kuzma
M
, et al.
Frequency of a tau genotype in amyotrophic lateral sclerosis
.
J Neurol Sci
.
2005
Sep
;
236
(
1-2
):
13
6
.
[PubMed]
0022-510X
9.
Popović
M
,
Fabjan
A
,
Mraz
J
,
Magdič
J
,
Glavač
D
,
Zupan
A
, et al.
Tau protein mutation P364S in two sisters: clinical course and neuropathology with emphasis on new, composite neuronal tau inclusions
.
Acta Neuropathol
.
2014
Jul
;
128
(
1
):
155
7
.
[PubMed]
0001-6322
10.
Lin
HC
,
Lin
CH
,
Chen
PL
,
Cheng
SJ
,
Chen
PH
.
Intrafamilial phenotypic heterogeneity in a Taiwanese family with a MAPT p.R5H mutation: a case report and literature review
.
BMC Neurol
.
2017
Sep
;
17
(
1
):
186
.
[PubMed]
1471-2377
11.
Štrafela
P
,
Pleško
J
,
Magdič
J
,
Koritnik
B
,
Zupan
A
,
Glavač
D
, et al.
Familial tauopathy with P364S MAPT mutation: clinical course, neuropathology and ultrastructure of neuronal tau inclusions
.
Neuropathol Appl Neurobiol
.
2018
Oct
;
44
(
6
):
550
62
.
[PubMed]
0305-1846
12.
Fang
P
,
Xu
W
,
Wu
C
,
Zhu
M
,
Li
X
,
Hong
D
.
MAPT as a predisposing gene for sporadic amyotrophic lateral sclerosis in the Chinese Han population
.
Neural Regen Res
.
2013
Nov
;
8
(
33
):
3116
23
.
[PubMed]
1673-5374
13.
Lamp
M
,
Origone
P
,
Geroldi
A
,
Verdiani
S
,
Gotta
F
,
Caponnetto
C
, et al.
Twenty years of molecular analyses in amyotrophic lateral sclerosis: genetic landscape of Italian patients
.
Neurobiol Aging
.
2018
Jun
;
66
:
179.e5
16
.
[PubMed]
0197-4580
14.
Noelker
LS
,
Browdie
R
.
Sidney Katz, MD: a new paradigm for chronic illness and long-term care
.
Gerontologist
.
2014
Feb
;
54
(
1
):
13
20
.
[PubMed]
0016-9013
15.
Cedarbaum
JM
,
Stambler
N
,
Malta
E
,
Fuller
C
,
Hilt
D
,
Thurmond
B
, et al.;
BDNF ALS Study Group (Phase III)
.
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function
.
J Neurol Sci
.
1999
Oct
;
169
(
1-2
):
13
21
.
[PubMed]
0022-510X
16.
Snowden
JS
,
Adams
J
,
Harris
J
,
Thompson
JC
,
Rollinson
S
,
Richardson
A
, et al.
Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations
.
Amyotroph Lateral Scler Frontotemporal Degener
.
2015
;
16
(
7-8
):
497
505
.
[PubMed]
2167-8421
17.
Di Fonzo
A
,
Ronchi
D
,
Gallia
F
,
Cribiù
FM
,
Trezzi
I
,
Vetro
A
, et al.
Lower motor neuron disease with respiratory failure caused by a novel MAPT mutation
.
Neurology
.
2014
Jun
;
82
(
22
):
1990
8
.
[PubMed]
0028-3878
18.
Bukar Maina
M
,
Al-Hilaly
YK
,
Serpell
LC
.
Nuclear tau and its potential role in Alzheimer’s disease
.
Biomolecules
.
2016
Jan
;
6
(
1
):
9
.
[PubMed]
2218-273X
19.
Zhang
CC
,
Zhu
JX
,
Wan
Y
,
Tan
L
,
Wang
HF
,
Yu
JT
, et al.
Meta-analysis of the association between variants in MAPT and neurodegenerative diseases
.
Oncotarget
.
2017
Jul
;
8
(
27
):
44994
5007
.
[PubMed]
1949-2553
20.
Lewis
J
,
McGowan
E
,
Rockwood
J
,
Melrose
H
,
Nacharaju
P
,
Van Slegtenhorst
M
, et al.
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein
.
Nat Genet
.
2000
Aug
;
25
(
4
):
402
5
.
[PubMed]
1061-4036
21.
Higuchi
M
,
Ishihara
T
,
Zhang
B
,
Hong
M
,
Andreadis
A
,
Trojanowski
J
, et al.
Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration
.
Neuron
.
2002
Aug
;
35
(
3
):
433
46
.
[PubMed]
0896-6273
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.